Home Hepatitis B and D Protocols: Volume 2: Immunology, Model Systems, and Clinical Studies by Robert K. Hamatake (Editor); Johnson Y. Lau (Editor) (ISBN: 9781588291080)

Stock photo: cover may vary

Hepatitis B and D Protocols: Volume 2: Immunology, Model Systems, and Clinical Studies Hardback - 2004

Name: Hepatitis B and d Protocols: Immunology Model Systems, and Clinical Studies
Price: 7.96 USD
Availability: InStock
Author: Johnson Y. N. Lau et Robert K. Hamatake
ISBN: 9781588291080

by Robert K. Hamatake (Editor); Johnson Y. Lau (Editor)

Add to wish list

Browse more copies for sale ↓

Reader reviews for Hepatitis B and D Protocols: Volume 2: Immunology, Model Systems, and Clinical Studies

Write a review for this book

Important Terms and Guidelines

Please focus on the book’s content and context. Also, add any personal comments as to how you enjoyed the book. Substantiate your likes and dislikes. You may make comparisons to other books.
Reviews must be at least 140 characters in length.
Please do not reveal critical plot elements.
This is not a help line. Contact customer support if you need help.

Your review must not include:

Obscenities, discriminatory language, or other insulting language not suitable for public domain
Advertisements, “spam” content, or references to other products, offers or websites.
Email addresses, URLs, phone numbers, physical addresses or other contact information.
Overly critical comments about other reviews or reviewers
Time-sensitive material (i.e. promotional tours, seminars, lectures, etc.)
Availability, price, or alternative ordering/shipping information

From the publisher

Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (HBV). For them, the vaccine, as currently applied, has no value. Given the possible consequences of HBV infection, the number of those chronically infected with HBV presents an enormous public health challenge. For example, the major etiology of hepatocellular carcinoma (HCC) is chronic infection with HBV. Although fifth in cancer incidence, worldwide, HCC/liver cancer is the third leading cause of cancer death. The high mortality as- ciated with HCC arises because the disease is often detected late and is unresponsive to treatment. The number of deaths caused by PHCC is expected to rise over the next 20 years. Those chronically infected with HBV have a life risk of death to HCC of between 10 and 25%. Even the limited efficacy of drugs for the treatment of chronic HBV helps underscore the point that this disease is responsive to therapy. Drugs that target the polymerase (e. g., hepsera and lamivudine) and interferon alpha represent two distinct strategies and show that both conventional antiviral and immunothe- peutic approaches can be used in management. However, the current inventory of therapeutics is inadequate. Interferon alpha is of limited value, only parenterally ava- able, and fraught with adverse reactions.

First line

The duck hepatitis B virus (DHBV) is a species-specific virus that causes either transient (acute) or persistent infections, primarily in hepatocytes in the liver, with release of high titers of infectious virions and noninfectious "empty" surface antigen particles into the bloodstream.

From the rear cover

Despite the availability of an effective vaccine, there are still 400 million people worldwide who are chronically infected with the hepatitis B and D viruses (HBV and HDV), and more work still needs to be done in all of the key areas of managing the disease. In Hepatitis B and D Protocols, leading investigators and clinicians have joined forces to create a broad-ranging collection of cutting-edge techniques for the study of HBV and HDV infections and for the development of therapies to treat them. In this second of two volumes, Immunology, Model Systems, and Clinical Studies, the authors focus on protocols for the study of host immune responses to infection, in vitro and in vivo models of infection, and the development of antivirals. Each fully tested protocol is described in step-by-step detail by an established expert in the field and includes a background introduction outlining the principle underlying the technique, equipment and reagent lists, and tips on troubleshooting and avoiding known pitfalls. An accompanying first volume, Detection, Genotypes, and Characterization, contains user-friendly protocols for the identification and quantification of viral markers, the detection and impact of viral variants, and the study of the viral life cycle.
Taken together, Hepatitis B and D Protocols, Volume 1: Detection, Genotypes, and Characterization and Volume 2: Immunology, Model Systems, and Clinical Studies offer both new and experienced investigators an encyclopedic collection of powerful tools for studying HBV and HDV infections, as well as an essential resource for finding new therapies to treat chronically infected patients.

Details

Title Hepatitis B and D Protocols: Volume 2: Immunology, Model Systems, and Clinical Studies
Author Robert K. Hamatake (Editor); Johnson Y. Lau (Editor)
Binding Hardback
Edition U. S. EDITION
Pages 572
Volumes 1
Language ENG
Publisher Humana
Publication date 2004-01-28
Illustrated Yes
Features Bibliography, Illustrated, Index
ISBN 9781588291080 / 1588291081
Weight 2.04 lbs (0.93 kg)
Dimensions 9.24 x 6.14 x 1.28 in (23.47 x 15.60 x 3.25 cm)
Category Medical / Nursing
Library of Congress subjects Delta-associated agent, Delta infection
Library of Congress Catalogue Number 2003011624
Dewey Decimal Code 616.362

More Copies for Sale

Stock photo: cover may vary

Hepatitis B and d Protocols: Immunology Model Systems, and Clinical Studies

by Johnson Y. N. Lau et Robert K. Hamatake

Used
Very good
Hardback

Condition: Very good
Binding: Hardcover
ISBN 10 / ISBN 13: 9781588291080 / 1588291081
Quantity available: 1
Seller: AMMAREAL

Biblio Top Seller
Item price: A$11.49

A$37.54 Delivery to USA

Show details

Description:

Humana Press Inc., 2004. Hardcover. Very Good. Former library book. Slight signs of wear on the cover. Stains on the edge. Edition 2004. Ammareal gives back up to 15% of this item's net price to charity organizations.